Floatz logo

IERAMILIMAB

Diffuse Large B Cell Lymphoma

Novartis Pharmaceuticalsmonoclonal_antibodyPhase 2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
73/ 100

Competitive context

271 Active assets in the Diffuse Large B Cell Lymphoma cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 2/3A
Evomela
Ruijin Hospital
Phase 4BBB
Axicabtagene Ciloleucel
Ruijin Hospital
Phase 4BBB
FILGRASTIM
Ruijin Hospital
Phase 3BBB
PREDNISONE TABLETS
Beth Israel Deaconess Medical Center
Phase 4BBB

View all 50 →

Same molecule, other indications

IERAMILIMAB is also rated in:

triple-negative breast carcinomaDormant
B
Indicative ·
58 / 100
View asset →
soft tissue sarcomaDormant
B
Indicative ·
57 / 100
View asset →
castration-resistant prostate carcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →